Sacubitril-Valsartan (Entresto®) Product Review

In this review:

This review discusses the evidence in support of the use of sacubitril/valsartan (Entresto®) for the
treatment of patients with chronic heart failure and reduced ejection fraction. Sacubitril/valsartan is the
first of a new class of agents, the angiotensin receptor neprilysin inhibitors, which have been designed
to block the renin-angiotensin-aldosterone system and enhance natriuretic peptides, thereby improving
neurohormonal balance in patients with heart failure.

Download PDF Subscribe